About NOXXON
NOXXON’s oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor micro-environment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 will deliver top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients in 2018.
| 2018, April 10 - Check out our latest analyst report by Aurgalys Value |
Press ReleaseBerlin, Germany
2018, June 15 8:00 a.m. NOXXON announces that it has secured additional financing 2018, June 06 6:00 p.m. NOXXON issues seventh tranche of ODIRNANE bonds 2018, May 29 8:00 a.m. NOXXON provides clinical update prior to American Society of Clinical Oncology (ASCO) annual conference |
EventsAram Mangasarian Aram Mangasarian Aram Mangasarian Aram Mangasarian |